Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
49
resultados
Última actualización
11/11/2026 [06:45:00]
Resumen de: US20260347948A1
0000 Methods for treating and/or assessing a subject having a symptomatic multiple myeloma or a precursor thereof, where the methods involve characterizing a plasma cell dyscrasia (e.g., monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, multiple myeloma, plasma cell leukemia) in a biological sample from a subject as being high, medium, or low risk by assigning to the plasma cell dyscrasia a multiple myeloma (MM)-like score. The methods may involve sequencing DNA from the biological sample using whole-genome sequencing (WGS).
Resumen de: US20260345618A1
The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1/2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, Pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.
Resumen de: US20260347349A1
0000 CXCR4 antagonists and pharmaceutical formulations thereof are disclosed. The compounds and pharmaceutical formulations disclosed herein can be used to antagonize the CXCR4 pathway for mobilizing stem cells or treating a condition, disorder, or disease associated with the CXCR4 pathway. Exemplary conditions, disorders, and diseases relevant to this disclosure include HIV infections, WHIM syndrome, Waldenström macroglobulinemia, chronic neutropenia, primary immune-deficiency, aplastic anemia, hypoplastic myelodysplastic syndrome, acute respiratory distress syndrome (ARDS), ankylosing spondylitis, autoimmune diseases, and cancers.
Resumen de: US20260345647A1
0000 A treatment method, comprising using a drug containing AST-3424, AST-3423 or AST-2870 and a salt thereof, an ester thereof, a solvate thereof, or an isotopic isomer thereof in combination with a drug containing cytarabine or daunorubicin and a salt thereof, an ester thereof, a solvate thereof, or an isotopic isomer thereof to treat leukemia and lymphoma patients. Where the concentration of daunorubicin or cytarabine is far lower than the clinical dosage thereof, there is no need to limit patients to those with higher (overexpression, excess) AKR1C3 protein or RNA expression; the combination of AST-3424 and cytarabine or daunorubicin still has a remarkable inhibitory effect on the in-vitro proliferation of leukemia or lymphoma cells, and the combination has a relatively good inhibitory effect on the in-vitro proliferation of cell lines with different levels of AKR1C3 protein or RNA expression. Therefore, the described combination protocol is expected to be developed into a new treatment protocol for treating leukemia and lymphoma without limiting the level of AKR1C3 enzyme expression in patients.
Resumen de: US20260345683A1
0000 The present study of the regulatory T phenotype of Sézary cells led to the discovery of the overexpression of CD81 by Sézary cells. CD81 has also been shown to be a relevant therapeutic target in the treatment of Sézary syndrome, NK/T lymphoma, hepatosplenic T-cell lymphoma and acute T cell leukemia. CD81 therefore appears as a diagnostic marker and as a therapeutic target in T-cell malignancies. Accordingly, the present invention relates CD81 as a biomarker and biotarget in T-cell malignancies.
Resumen de: US20260347354A1
The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
Resumen de: WO2026229443A1
The invention relates to a composition or a kit comprising a Toll-like receptor agonist and an Interleukin-7 (IL-7) antagonist as well as methods and uses for treating or preventing lymphoblastic leukemia.
Resumen de: US20260345680A1
0000 Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma (MM) targeting B-cell maturation antigen (BC-MA) induces high overall response rates. However, relapse occurs frequently and novel strategies for CAR-T cells targeting MM cells are needed. CAR-T cells targeting CD38 represent a potential alternative, but expression of CD38 on activated T cells and other hematopoietic cells raises concerns about the efficacy and safety of such therapy. Here, the inventors developed DCAR, a double CAR system targeting CD38 and SLAMF7 (CS1) through split activation and co-stimulation receptors, respectively. Furthermore, the inventors show that CRISPR/Cas9 inactivation of the CD38 gene enhances the anti-MM activity of DCAR-T in vitro. Edited DCAR-T developed strong responses specifically against MM cells expressing both the CD38 and the CS1 antigens in vitro and in vivo. Importantly, the inventors bring evidence that, unlike anti-CD38 CAR-T, which elicited a severe immune reaction against hematopoietic cells in a humanized mouse model, DCAR-T showed no sign of toxicity. Accordingly, the present invention relates to novel dual split CAR-T cells and uses thereof for the treatment of CD38-positive hematological malignancies.
Resumen de: US20260347775A1
Methods of expanding tumor infiltrating lymphocytes (TILs), including peripheral blood lymphocytes and marrow infiltrating lymphocytes, from blood and/or bone marrow of patients with hematological malignancies, such as liquid tumors, including lymphomas and leukemias, and uses of such expanded TILs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.
Resumen de: US20260345486A1
0000 An improved method of treating cancers CD19 CAR T cells by administering the CD19 CAR T cells to the central nervous system, e.g., by intracerebroventricular administration, is described.
Resumen de: WO2026227249A1
Provided are a culture medium and a culture method for culturing human primary B-cell lymphoma cells. The culture medium for culturing human primary B-cell lymphoma cells comprises an anti-immunoglobulin M antibody, a recombinant human CD40 ligand, CpG oligodeoxynucleotide 2006, superoxide dismutase, interleukin-2, interleukin-21, and interleukin-4. Also provided are B-cell lymphoma cells obtained by in vitro culturing using the culture medium, and a method and the use thereof in the efficacy evaluation and screening of drugs.
Resumen de: US20260350412A1
Methods of speeding the training of a convolutional neural network (CNN) to classify new images of biological cells captured by an imaging flow cytometer (IFC) are disclosed. Transfer learning with and without mapping is used based on the selection of pre-trained CNN to be used. New images of biological cells can be classified with new classes that are provided such as classes for red blood cells and classes for DNA damage of lymphoma biological cells.
Resumen de: WO2026231609A1
Provided herein are methods of treating certain B cell lymphomas comprising administering a T-cell engager (TCE) in combination with 3-(6-(((3R,4R)-1-(5-chloro-4-((1-methyl-2-oxoindolin-5-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-yl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione or a pharmaceutically acceptable salt thereof.
Resumen de: WO2026228549A1
The present invention relates to an antigen-binding molecule that specifically binds to CD38, a conjugate comprising same, and the medical use thereof. Specifically, the present invention relates to an antibody-drug conjugate that specifically binds to CD38 and the use thereof in a drug for treating multiple myeloma.
Resumen de: EP4834352A1
0001 The invention relates to a composition or a kit comprising a Toll-like receptor agonist and an Interleukin-7 (IL-7) antagonist as well as methods and uses for treating or preventing lymphoblastic leukemia.
Resumen de: EP4834348A1
The present application relates to a pharmaceutical composition comprising an active ingredient Compound 1, a pharmaceutically acceptable polymeric carrier, a surfactant, and other pharmaceutically acceptable excipients; wherein said active ingredient, said polymeric carrier, and optionally at least a portion of said surfactant are present in the form of a solid dispersion. The present application discloses for the first time a pharmaceutical composition comprising Compound 1, which has stable product quality and good bioavailability. Based on the property of Compound 1 as a JAK inhibitor, the composition has broad application prospects for alopecia areata, vitiligo, atopic dermatitis, psoriasis, membranous nephropathy, ankylosing spondylitis, peripheral T-cell lymphoma, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, etc.
Resumen de: WO2026226955A1
The invention provides novel compounds of Formulas (I)-(III), as described herein. Also provided are compositions of these compounds, methods of making the compounds, and methods 5 of using the compounds. The compounds can be used to regulate cholesterol homeostasis and to treat conditions and diseases associated with cholesterol homeostasis, including lysosomal lipid storage disorders such as Niemann-Pick Disease type C and cancers such as leukemia.
Resumen de: US20260338776A1
In one embodiment, a reagent kit for analysis of blood cells by a spectral flow cytometer having at least three lasers and at least thirty-eight detectors is disclosed. The reagent kit includes a plurality of vials with a plurality of fluorochromes respectively conjugated to a plurality of antibody clones for markers of cells in peripheral blood mononuclear cells (PBMC) and whole blood to analyze and identify healthy cells from leukemia cells in a biological sample in a single sample test tube. The pairing of reagents and fluorochromes in the reagent kit are identified in a simplified format by a flow cytometer panel for use with the spectral flow cytometer.
Resumen de: WO2026227004A1
The present invention is directed to substituted indolenine inhibitors of PIM1 kinase, pharmaceutical compositions comprising them, and their use in the treatment of PIMl-overexpressing diseases including breast, prostate, lung, gastric, colorectal, pancreatic, renal, testicular, and head and neck cancers, as well as lymphomas, acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myeloid leukemia (CML).
Resumen de: US20260337562A1
Hematopoietic stem progenitor cells (HSPCs) are multipotent, self-renewing, progenitor cells capable of generating every type of blood cell arising from both the lymphoid and myeloid lineages. Since many types of cancer, including leukemia, lymphoma, and myeloma, affect the development, function, and viability of a number of blood cells, finding a means of producing HSPCs has become an important area of research. Disclosed are CD34+hematopoietic stem progenitor cells (HSPCs) generated from induced pluripotent stem cells (IPSCs) and T cells generated from IPSCs under minimal cytokine conditions, and methods of generating and using the same for the treatment of diseases and disorders.
Resumen de: US20260335342A1
A method for treating lymphoma is provided. A pharmaceutical composition for treatment of lymphoma, including BCV, a pharmaceutically acceptable salt thereof, or a solvate thereof is used. The lymphoma may be EBV-positive lymphoma. The lymphoma may be MYC-positive lymphoma. The pharmaceutical composition may be used in combination with a chemotherapeutic agent.
Resumen de: AU2025266243A1
Disclosed herein is a platform technology for designing T cell engagers. Examples of such T cell engagers and nucleic acids (e.g., mRNAs) encoding same as well as lipid nanoparticles comprising nucleic acids (e.g., mRNAs) encoding the T cell engagers are provided. Such T cell engagers can be used to treat cancers such as FCRH5+, GPRC5D+, and/or BCMA+ cancers, including hematological malignancies such as multiple myeloma (e.g., advanced MM, RRMM), B cell lymphoma, and myeloid cancers.
Resumen de: EP4831179A1
The invention provides 4,6-disubstituted-7H-pyrrolo2,3-dpyrimidines of general formula I,wherein all the variables are defined in the claims. The compounds of this invention are potent and selective inhibitors of CDK9 and are useful in the treatment of leukemias, solid tumors, lymphomas, neutrophilic dermatoses or netrophilic diseases.
Resumen de: WO2025134050A1
Embodiments of the present disclosure relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of a BCMA x GPRC5D x CD3 trispecific antibody or trispecific binding fragment thereof, to the subject to the subject to treat the multiple myeloma.
Nº publicación: WO2026221060A1 22/10/2026
Solicitante:
JAPANESE FOUNDATION FOR CANCER RES [JP]
\u516C\u76CA\u8CA1\u56E3\u6CD5\u4EBA\u304C\u3093\u7814\u7A76\u4F1A
Resumen de: WO2026221060A1
The present invention addresses the problem of providing a biomarker for predicting the prognosis of IDD-LPD. The prognosis of IDD-LPD is predicted by using the presence or absence of deletion of a specific region in a human chromosome or the presence or absence of a mutation in a specific human gene region as an indicator.
BOPI
Sede Electrónica
